Healthy Skepticism Library item: 3508

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: Journal Article

Piroxicam
1987 May; 1-7

Abstract:

MaLAM has provided a detailed reply to Pfizer regarding the company’s earlier letter about marketing piroxicam. MaLAM does not feel that Pfizer has adequately dealt with the safety issues raised earlier.

Keywords:
*analysis/developing countries/piroxicam/Pfizer/NSAID/ nonsteroidal anti-inflammatory drugs/ company responses/ quality of prescribing/ safety & risk information/MaLAM/Medical Lobby for Appropriate Marketing/EVALUATION OF PROMOTION: DRUG SAFETY/PROMOTION AND HEALTH NEEDS: PROMOTION IN DEVELOPING COUNTRIES